Reply to Anthony et al., "protecting Pyrazinamide, a priority for improving outcomes in multidrug-resistant tuberculosis treatment

M. O. Fofana, David Wesley Dowdy

Research output: Contribution to journalLetter

Original languageEnglish (US)
Article numbere00427-17
JournalAntimicrobial Agents and Chemotherapy
Volume61
Issue number6
DOIs
StatePublished - Jun 1 2017

Fingerprint

Pyrazinamide
Multidrug-Resistant Tuberculosis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

@article{e4fd969ba5c24ac9a128bbe10cdb8351,
title = "Reply to Anthony et al., {"}protecting Pyrazinamide, a priority for improving outcomes in multidrug-resistant tuberculosis treatment",
author = "Fofana, {M. O.} and Dowdy, {David Wesley}",
year = "2017",
month = "6",
day = "1",
doi = "10.1128/AAC.00427-17",
language = "English (US)",
volume = "61",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Reply to Anthony et al., "protecting Pyrazinamide, a priority for improving outcomes in multidrug-resistant tuberculosis treatment

AU - Fofana, M. O.

AU - Dowdy, David Wesley

PY - 2017/6/1

Y1 - 2017/6/1

UR - http://www.scopus.com/inward/record.url?scp=85019735395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019735395&partnerID=8YFLogxK

U2 - 10.1128/AAC.00427-17

DO - 10.1128/AAC.00427-17

M3 - Letter

C2 - 28539499

AN - SCOPUS:85019735395

VL - 61

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

M1 - e00427-17

ER -